NRAS and neoplasm: Pharmacological co-targeting of NFATc2 and EZH2 exerted significant anti-tumor effects in distinct melanoma subsets, including BRAF-mutant but BRAF-inhibitor-resistant cell lines, as well as NRAS mutant and BRAF/NRAS wild-type tumors.